Jenny Alltoft | Head of Global Biosimilars
Pfizer

Jenny Alltoft, Head of Global Biosimilars, Pfizer

With nearly 30 years’ experience in pharmaceutical portfolio management, Jenny has a proven track record covering all aspects of a product’s lifecycle, including from early R&D to loss of exclusivity. She is a skilled coach and authentic leader, dedicated to unlocking the potential in organizations and team members.  

In her current role as Global Leader of Pfizer’s Biosimilars business, Jenny leads global strategy, alliance management, M&A integration, market development and commercialization of biosimilars.  
Prior to this role, Jenny was General Manager for Pfizer’s Established Products business unit in Australia and New Zealand, managing a portfolio of more than 150 branded and generic medicines used in general practice and hospital settings. 
Additional career highlights include successfully managing and growing the Norvasc® brand and leading the global team responsible for developing the commercialization strategy for Chantix®. Jenny’s ability to incorporate consumer insights into marketing strategies contributed to a leadership role in establishing the Patient and Marketing Centers of Expertise.  

Throughout her career, she has demonstrated a passion for business growth and team leadership, with exemplary abilities in change management and cross-functional partnerships. In 2004, Jenny was the recipient of the Healthcare Business Women’s Association Rising Star Award, reflecting her strengths and achievements in healthcare.

Appearances:



Biosimilars Day 1 - Monday 29th October 2018 @ 09:00

An update on Pfizer’s biosimilar goals for 2019

  • Policies around sustainability after 10 years of biosimilars in Europe
  • Global presence in other regions, non-compatibles and standards

Biosimilars Day 1 - Monday 29th October 2018 @ 09:40

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

    sting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gain-sharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines

Biosimilars Day 1 - Monday 29th October 2018 @ 09:40

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

    sting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gain-sharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines
last published: 26/Sep/18 12:15 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.

 

Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October

Sign Up for Event Updates